IFLR1000

Pfizer $340 million acquisition of Therachon

None
Private acquisition
Select tab

$ 340 million

Announced

None

Overview:

  • New York listed pharmaceutical company Pfizer has agreed to acquire biotechnological company Therachon.
  • The deal is valued at $340 million but is set to increase by $470 million in additional payments subject to completion of objectives.

Rajeeb Gurung - Researcher

Jurisdiction:

Switzerland

Deal type:

Private acquisition

Practice area:

M&A

Governing laws:

United States
Switzerland

Industry sector:

Pharmaceuticals and life sciences

Firms:
Arnold & Porter

Party: Pfizer (Acquirer)

Lawyers: Lowell Dashefsky, Rory Greiss

Cooley

Party: Therachon (Target)

Homburger

Party: Therachon (Target )

Lawyer: Dieter Gericke

Lenz & Staehelin

Party: Pfizer (Acquirer)

Lawyer: Stephan Erni

Related deals